Managlinat dialanetil (MB06322) is an orally bioavailable inhibitor of fructose 1,6-bisphosphatase (FBPase) for the treatment of type 2 diabetes
In Vivo
Managlinat dialanetil dose-dependently inhibits GNG as well as lower basal and postprandial blood glucose levels in Zucker diabetic fatty (ZDF) rats after oral administration . MCE has not independently confirmed the accuracy of these methods. They are for reference only.